Cardiomyopathy classification has been subject to revisions for >60 years. The new MOGE(S) classification system, which incorporates information on structural and functional abnormalities, organ involvement, genetics, aetiology, and disease severity, is a step towards a globally accepted nomenclature, but needs to be applicable in all health-care systems around the world.
Why do we need a new classification system for cardiomyopathy, such as MOGE(S), 1 which was published in the Journal of the American College of Cardiology in December 2013? The term 'cardio myopathy' has been the subject of various, and some times conflicting, systems of nomen clature and classification since the 1950s. The specific term came into favour over several years, between the time of Brigden (1957) and the International Symposium on Cardiomyopathies, which was held in 1971 in Tiervlei, South Africa. 2 At least 27 different terms were used for cardiomyo pathy in South Africa in the 1960s-some even by the same authors in different pub lications-which was indicative of the lack of consensus on the definition and clas sification of cardiomyopathy at the time. 2 A standardized nomenclature was, however, not agreed upon until a decade later. 3 A report of the WHO/International Society and Federation of Cardiology (ISFC) Task Force on the Definition and Classification of Cardiomyopathies in 1980 divided the con dition into heart muscle diseases of unknown cause, and specific heart muscle diseases caused by conditions other than systemic or pulmonary hypertension, coronary artery disease, congenital cardiac anomalies, and valvular heart disease. 3 The structural and functional classification into dilated, hyper trophic, restrictive, and unclassified cardio myopathies was coined at this time and has endured to this day.
Three major revisions of the definition and classification of cardiomyopathy have occurred since 1980. The 1995 WHO/ISFC revision removed the distinction between idiopathic cardiomyopathies and specific heart muscle diseases. 4 This classification system introduced poorly defined terms such as 'ischaemic cardiomyopathy' , 'val vular cardiomyopathy' , and 'hypertensive cardio myopathy' , which extended the defin ition of cardiomyopathy to cover almost all of cardiology-and possibly caused con fusion in the minds of medical students and their teachers alike as to the meaning of cardiomyopathy. In the language of the members of the first 1980 WHO/ISFC Task Force, further extension of the classification to include ischaemic heart disease, hyper tension, and valvular heart disease "would have so widened its scope as to render it useless". 3 In 2006, the AHA defined cardio myopathies as a heterogeneous group of diseases of the myocardium associated with mechanical or electrical dysfunction, or both, that usually (but not invariably) exhibit inappropriate ventricular hyper trophy or dilatation and are due to a variety of causes that frequently are genetic. 5 According to this definition, cardiomyo pathies, which included channel opathies, were either confined to the heart or were part of generalized systemic disorders, often leading to cardiovascular death or progressive disability associated with heart failure. This broad classification scheme, which has been supported by others, 6 was not intended to provide precise method ologies or strategies for the clinical diagno sis of patients with cardiomyopathy. 5 Finally, in 2008, the ESC redefined cardiomyopathy as a structural and functional abnormality of the myocardium resulting in a dilated, hypertrophic, restrictive, or other cardio myopathic phenotype that was not caused by hypertension, coronary artery disease, valvular heart disease, or congenital heart disease. 7 Furthermore, cardiomyopathy was subclassified into familial (genetic) or non familial (nongenetic) types. I have found that the ESC classification lends itself to the clini cal evaluation of patients with unexplained heart failure better than previous schema. 6 In the MOGE(S) system, Arbustini and colleagues present a new notation that addresses five attributes of cardiomyo pathies: the structural and functional abnor mality (M), the extent of organ involvement (O), whether the disease is a genetic or nongenetic condition (G), the nature of the molecular genetic defect or other aetiology if known (E), and the optional inclusion of stage of heart failure and degree of effort intolerance (S; Box 1). 1 This scheme endorses the ESC definition of cardiomyopathy, and extends the classification system to include an explicit description of the extent of organ involvement, and stage of heart failure. The MOGE(S) system allows a comprehensive summary of the clinical and genetic status of a family with inherited cardio myopathy after screening is completed. The scheme has the potential to improve the characterization of patients with cardiomyopathy, and stand ardize the reporting of cardiomyopathy in epidemiological studies.
Several areas, in addition to those noted in the eloquent critique by Perry Elliot, 8 need to be addressed before this new clas sification scheme can achieve global applic ability. First, the aetiological notation does not include important groups such as tachycardiainduced cardiomyopathy, endocrineassociated cardiomyopathy (such as thyroid heart disease), and peripartum cardio myopathy. Furthermore, the aetio logical diagnosis remains elusive in the major ity of patients with tropical endomyocardial fibrosis, which is probably the leading cause of restrictive cardiomyopathy in the world. An aetiological category for unexplained (or idiopathic) cardiomyopathy would improve the clinical utility of this scheme. Second, the scheme would be enhanced by the inclusion of a graded risk of sudden cardiac death, in conjunction with the staging of heart failure.
Lethal ventricular arrhythmias are the domi nant mode of death in most forms of cardio myopathy, and markers of sudden cardiac death are known in hypertrophic cardiomyo pathy and arrhythmogenic right ventricular cardiomyopathy. Even in dilated cardiomyo pathy, more than half of deaths are sudden and have been associated with arrhythmias. 9 The factors that are commonly associated with a high risk of sudden arrhythmic death are depressed ventricular function, sustained or nonsustained ventricular tachycardia, and a history of syncope. The utility of the MOGE(S) scheme to predict outcome would be enhanced by the inclusion of risk factors for sudden a rrhythmic death in patients with cardiomyopathy.
Finally, the complexity of the MOGE(S) classification system might be a deterrent to its use in routine clinical practice. Addi tion ally, the information that is required, such as the molecular genetic diagno sis, is available in only a few centres and countries in the world. The authors of the MOGE(S) nomenclature have develope d an Internetbased application (http://moges. biomeris.com) that can be used in daily clinical practice to complete the descriptive classification of cardiomyopathy. The pro vision of an intuitive tool with dropdown lists, user support, and easy integration into patient records will facilitate the uptake of this classification system in busy clinics. MOGE(S) is an admirable achievement on the path towards a globally accepted nomenclature for cardiomyopathy. The efforts to reach a consensus on the defin ition and classification of cardiomyopathy have been spearheaded by singlecountry or s inglecontinent societies, such as the AHA and ESC. Future development of the MOGE(S) classification should include par ticipation from experts from all regions of the world, including Africa, where cardio myopathies are endemic. 10 The MOGE(S) nosology provides a sound basis on which a global consensus on the definition and classification of cardiomyopathy can be achieved, under the auspices of the World Heart Federation and its global affiliates. 
